Company profile
DIGISTAIN - The UKs First Breast Cancer Risk Profiling Technology -
DIGISTAIN is a Digital Solution To Cancer Grading And Prognosis approved by the UKs Medicines & Healthcare products Regulatory Agency (MHRA)
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0NDQ2NDMwNGFkaXF6a2N4
Published 21 Nov 2024 05:10
AA | Transaction MzQzNzE4NjEwMmFkaXF6a2N4
Published 25 Sep 2024 11:37
Company registered at Companies House
Digistain develops a risk-profiling test for breast cancer, aiming to determine the most effective course of treatment.
Chris Phillips has formed a mid-IR Imaging Company, Digistain Ltd., (http://digistain.co.uk) incorporated just before Christmas 2019, Company number 12329264, with himself and Dr Hemmel Amrania as directors.
The company has been granted an IP patent portfolio, (previously operated by Imperial Innovations) and is actively seeking investors to commercialize his mid-IR cancer detection technology.
1 Oct 2024 to 31 Dec 2024
Most cancers are first discovered when they manifest themselves physically. In the case of breast, a lump is found, and a biopsy is taken with a hollow needle. The tissue sample is fixed in formalin, embedded in wax, and slices are stained with dyes and mounted on a microscope slide. The slide is then visually evaluated using an optical microscope, using ...
1 Jan 2023 to 30 Jun 2024
Digistain is a market-ready, UK-based clinical diagnostics company transforming breast cancer treatment to save time, money, and lives. Where current companion diagnostics delay treatment decisions for up to a month, our technology provides oncologists with decision-making data in just 15 minutes. This means chemotherapy can be avoided where appropriate a...
